Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients
| Autor: | Benjamin H. Kann, Martin T. King, Vikram Jairam, Michael S. Leapman, Wesley J. Talcott, Paul L. Nguyen, Skyler B. Johnson, Joseph A. Miccio, James B. Yu, Henry S. Park |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty business.industry Prostatectomy Urology medicine.medical_treatment Brachytherapy 030232 urology & nephrology Cancer medicine.disease Radiation therapy 03 medical and health sciences Prostate cancer 0302 clinical medicine medicine.anatomical_structure Prostate 030220 oncology & carcinogenesis Internal medicine Propensity score matching Medicine External beam radiotherapy business |
| Zdroj: | Prostate Cancer and Prostatic Diseases. 24:414-422 |
| ISSN: | 1476-5608 1365-7852 |
| DOI: | 10.1038/s41391-020-00291-3 |
| Popis: | BACKGROUND Comparative effectiveness research (CER) using national registries influences cancer clinical trial design, treatment guidelines, and patient management. However, the extent to which treatment selection bias (TSB) affects overall survival (OS) in cancer CER remains poorly defined. We sought to quantify the TSB effect on OS in the setting of low-risk prostate cancer, where 10-year prostate cancer-specific survival (PCSS) approaches 100% regardless of treatment modality. METHODS The Surveillance, Epidemiology, and End Results database was queried for patients with low-risk prostate cancer (cT1-T2a, PSA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink